DERM Dermira, Inc.

33.46
+0  (0%)
Previous Close 33.45
Open 33.65
Price To book 4.82
Market Cap 1.19B
Shares 35,675,000
Volume 88,059
Short Ratio 4.12
Av. Daily Volume 313,344

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first trial released October 2016 - endpoints met. Second trial data released December 8, 2016 - endpoints met. Data from third and final trial met primary endpoint - January 19, 2017. FDA filing due 3Q 2017.
Cimzia
Moderate-to-severe plaque psoriasis
Phase 3 trial initiation announced January 3, 2017. Data are due 1H 2018.
Olumacostat glasaretil (DRM01)
Acne
Phase 3 data released June 2016. NDA Filing 2H 2017.
Glycopyrronium tosylate (DRM04)
Primary axillary hyperhidrosis

Latest News

  1. Dermira, Inc. – Value Analysis (NASDAQ:DERM) : April 20, 2017
  2. Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : April 19, 2017
  3. Dermira to Present at Needham 16th Annual Healthcare Conference
  4. Xenon Pharma Dumps Acne Drug After Study Failure
  5. Novartis’ Cosentyx Shows Psoriasis Modification Potential (NVS, DERM)
  6. Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
  7. Dermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting
  8. Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  9. New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
  10. Dermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting
  11. Dermira to Present at Cowen and Company 37th Annual Health Care Conference
  12. Dermira, Inc. :DERM-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
  13. Dermira Prices $168.5 Million Public Offering of Common Stock
  14. Dermira reports 4Q loss
  15. Dermira Announces Proposed Public Offering of Common Stock
  16. Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  17. Dermira Data from DRM04 and Olumacostat Glasaretil Clinical Programs to Be Presented at American Academy of Dermatology Annual Meeting
  18. Dermira to Report Fourth Quarter and Full Year 2016 Financial Results
  19. Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference
  20. Dermira Psoriasis Drug Cimzia Did Well In Study